ATE518011T1 - Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn - Google Patents
Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohnInfo
- Publication number
- ATE518011T1 ATE518011T1 AT07755012T AT07755012T ATE518011T1 AT E518011 T1 ATE518011 T1 AT E518011T1 AT 07755012 T AT07755012 T AT 07755012T AT 07755012 T AT07755012 T AT 07755012T AT E518011 T1 ATE518011 T1 AT E518011T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- crohn
- patients
- peripheral blood
- cell receptor
- Prior art date
Links
- 208000011231 Crohn disease Diseases 0.000 title abstract 5
- 102000019034 Chemokines Human genes 0.000 title 1
- 108010012236 Chemokines Proteins 0.000 title 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title 1
- 210000000265 leukocyte Anatomy 0.000 title 1
- 210000005259 peripheral blood Anatomy 0.000 title 1
- 239000011886 peripheral blood Substances 0.000 title 1
- 102000003390 tumor necrosis factor Human genes 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79035406P | 2006-04-07 | 2006-04-07 | |
| PCT/US2007/008597 WO2007117611A2 (en) | 2006-04-07 | 2007-04-05 | Enhanced t cell receptor-mediated tumor necrosis factor superfamily and chemokine mrna expression in peripheral blood leukocytes in patients with crohn's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE518011T1 true ATE518011T1 (de) | 2011-08-15 |
Family
ID=38581650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07755012T ATE518011T1 (de) | 2006-04-07 | 2007-04-05 | Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7838239B2 (enExample) |
| EP (1) | EP2005175B1 (enExample) |
| JP (1) | JP5027209B2 (enExample) |
| CN (1) | CN101410714A (enExample) |
| AT (1) | ATE518011T1 (enExample) |
| WO (1) | WO2007117611A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1776471B9 (en) * | 2004-05-25 | 2013-12-18 | Hitachi Chemical Company, Ltd. | Method of measuring cancer susceptibility |
| JP4772055B2 (ja) * | 2004-10-20 | 2011-09-14 | 日立化成工業株式会社 | ｍＲＮＡの定量により薬剤の投与を選定する方法 |
| US12110555B2 (en) | 2004-12-08 | 2024-10-08 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease |
| US11268149B2 (en) | 2004-12-08 | 2022-03-08 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease |
| US10544459B2 (en) | 2004-12-08 | 2020-01-28 | Cedars-Sinai Medical Center | Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease |
| JP4945554B2 (ja) * | 2005-04-28 | 2012-06-06 | ヒタチ ケミカル リサーチ センター インコーポレイテッド | 食物サプリメントに対する個体変動評価のモデルとしての全血におけるｅｘｖｉｖｏ遺伝子発現 |
| WO2009070442A2 (en) | 2007-11-14 | 2009-06-04 | Hitachi Chemical Co. Ltd. | Fc receptor-mediated tumor necrosis factor superfamily mrna expression in peripheral blood leukocytes |
| DE102006051628A1 (de) | 2006-11-02 | 2008-05-08 | Daimler Ag | Abgasturbolader für eine Brennkraftmaschine |
| US20100015156A1 (en) * | 2007-03-06 | 2010-01-21 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease in children |
| US8486640B2 (en) | 2007-03-21 | 2013-07-16 | Cedars-Sinai Medical Center | Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease |
| EP2056110A1 (en) | 2007-10-31 | 2009-05-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment |
| US20110229471A1 (en) * | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| US9580752B2 (en) | 2008-12-24 | 2017-02-28 | Cedars-Sinai Medical Center | Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy |
| EP2992792B1 (en) * | 2010-11-11 | 2017-03-15 | Nestec S.A. | Beverage production machine and rinsing and/or descaling insert |
| US9902996B2 (en) | 2011-02-11 | 2018-02-27 | Cedars-Sinai Medical Center | Methods of predicting the need for surgery in crohn's disease |
| EP2734233B1 (en) * | 2011-07-18 | 2017-11-01 | Hitachi Chemical Co., Ltd. | Methods of predicting host responsiveness to cancer immunotherapies by ex vivo induction of leukocyte-function-associated mrnas |
| KR20240122922A (ko) | 2013-03-27 | 2024-08-13 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전 |
| EP4105236A1 (en) | 2013-07-19 | 2022-12-21 | Cedars-Sinai Medical Center | Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease |
| CN103865998B (zh) * | 2013-12-16 | 2016-04-20 | 周菊华 | 一种肿瘤免疫治疗效果的基因检测方法 |
| US20150257586A1 (en) * | 2014-03-11 | 2015-09-17 | Starbucks Corporation Dba Starbucks Coffee Company | Single-serve beverage production machine |
| US11028443B2 (en) | 2015-08-31 | 2021-06-08 | Showa Denko Materials Co., Ltd. | Molecular methods for assessing urothelial disease |
| CN109462996A (zh) | 2016-03-17 | 2019-03-12 | 西达-赛奈医疗中心 | 通过rnaset2诊断炎性肠病的方法 |
| WO2020232125A1 (en) | 2019-05-14 | 2020-11-19 | Prometheus Biosciences, Inc. | Tl1a patient selection methods, systems, and devices |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4925572A (en) | 1987-10-20 | 1990-05-15 | Pall Corporation | Device and method for depletion of the leukocyte content of blood and blood components |
| US4880548A (en) | 1988-02-17 | 1989-11-14 | Pall Corporation | Device and method for separating leucocytes from platelet concentrate |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US5491063A (en) | 1994-09-01 | 1996-02-13 | Hoffmann-La Roche Inc. | Methods for in-solution quenching of fluorescently labeled oligonucleotide probes |
| PT938320E (pt) | 1996-03-26 | 2010-09-22 | Michael S Kopreski | Método que permite a utilização de arn extracelular extraído de plasma ou de soro para detectar, monitorizar ou avaliar o cancro |
| US5683698A (en) | 1996-08-02 | 1997-11-04 | New England Deaconess Hospital | Formulation for alleviating symptoms associated with arthritis |
| US7514232B2 (en) | 1996-12-06 | 2009-04-07 | Becton, Dickinson And Company | Method for detecting T cell response to specific antigens in whole blood |
| US6183951B1 (en) * | 1997-04-11 | 2001-02-06 | Prometheus Laboratories, Inc. | Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy |
| US20020006613A1 (en) | 1998-01-20 | 2002-01-17 | Shyjan Andrew W. | Methods and compositions for the identification and assessment of cancer therapies |
| WO2000076492A1 (en) | 1999-06-15 | 2000-12-21 | Nutri-Logics, Inc. | Nutrient formulations for disease reduction, and related treatment and component screening methods |
| US6692916B2 (en) | 1999-06-28 | 2004-02-17 | Source Precision Medicine, Inc. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
| US20020048566A1 (en) | 2000-09-14 | 2002-04-25 | El-Deiry Wafik S. | Modulation of cellular apoptosis and methods for treating cancer |
| US7374881B2 (en) * | 2000-10-31 | 2008-05-20 | Hitachi Chemical Research Center, Inc. | Method for collecting and using nuclear mRNA |
| US20020182274A1 (en) | 2001-03-21 | 2002-12-05 | Kung-Ming Lu | Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| JP5236856B2 (ja) * | 2001-11-09 | 2013-07-17 | ライフ テクノロジーズ コーポレーション | 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定 |
| CA2467629A1 (en) | 2001-11-20 | 2003-05-30 | Oncomedx, Inc. | Methods for evaluating drug-resistance gene expression in the cancer patient |
| US7871619B2 (en) | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| FI20020078A7 (fi) | 2002-01-15 | 2003-07-16 | Danisco | Immuunijärjestelmän stimulointi polydextroosilla |
| US6878518B2 (en) | 2002-01-22 | 2005-04-12 | The Trustees Of The University Of Pennsylvania | Methods for determining steroid responsiveness |
| US7745180B2 (en) | 2002-04-24 | 2010-06-29 | Hitachi Chemical Co., Ltd. | Device and method for high-throughput quantification of mRNA from whole blood |
| EP1507548B1 (en) | 2002-05-27 | 2014-10-01 | CanImGuide Therapeutics AB | Method for determining immune system affecting compounds |
| AU2002953533A0 (en) | 2002-12-24 | 2003-01-16 | Arthron Limited | Fc receptor modulating compounds and compositions |
| EP1776471B9 (en) | 2004-05-25 | 2013-12-18 | Hitachi Chemical Company, Ltd. | Method of measuring cancer susceptibility |
| US8110347B2 (en) | 2005-04-15 | 2012-02-07 | Canimguide Therapeutics Ab | Diagnostic method for detecting cancer by measuring amount of cytokine like IL-6 |
| JP4945554B2 (ja) | 2005-04-28 | 2012-06-06 | ヒタチ ケミカル リサーチ センター インコーポレイテッド | 食物サプリメントに対する個体変動評価のモデルとしての全血におけるｅｘｖｉｖｏ遺伝子発現 |
| US7935482B2 (en) | 2005-09-27 | 2011-05-03 | Source Precision Medicine, Inc. | Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis |
| US20100190162A1 (en) | 2007-02-26 | 2010-07-29 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
-
2007
- 2007-04-05 JP JP2009504317A patent/JP5027209B2/ja not_active Expired - Fee Related
- 2007-04-05 US US12/296,425 patent/US7838239B2/en not_active Expired - Fee Related
- 2007-04-05 WO PCT/US2007/008597 patent/WO2007117611A2/en not_active Ceased
- 2007-04-05 EP EP07755012A patent/EP2005175B1/en not_active Not-in-force
- 2007-04-05 CN CNA2007800115431A patent/CN101410714A/zh active Pending
- 2007-04-05 AT AT07755012T patent/ATE518011T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101410714A (zh) | 2009-04-15 |
| JP5027209B2 (ja) | 2012-09-19 |
| EP2005175A2 (en) | 2008-12-24 |
| WO2007117611A3 (en) | 2008-08-07 |
| EP2005175A4 (en) | 2009-06-03 |
| US7838239B2 (en) | 2010-11-23 |
| US20090253133A1 (en) | 2009-10-08 |
| EP2005175B1 (en) | 2011-07-27 |
| JP2009535016A (ja) | 2009-10-01 |
| WO2007117611A2 (en) | 2007-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE518011T1 (de) | Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn | |
| ATE473781T1 (de) | Gerät zum nachweis von arrhythmie in einem medizinprodukt | |
| DE602007009483D1 (de) | Vorrichtung zur erkennung und behandlung von depressionen | |
| AU2003295644A8 (en) | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor | |
| WO2004053066A3 (en) | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy | |
| ATE448732T1 (de) | Sammlung von informationen zur aktivität und schlafqualität mit einem medizinprodukt | |
| NO996229L (no) | Heparanase spesifikke molekylære prober og deres anvendelse i forskning og medisin | |
| ATE490726T1 (de) | Biofeedback-system und anzeigevorrichtung | |
| MX2012001716A (es) | Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf. | |
| ATE462973T1 (de) | Diagnose und prävention der krebszellinvasion | |
| WO2009037454A3 (en) | Cancer marker and therapeutic target | |
| CY1120433T1 (el) | Θεραπεια αγωνιστων μελατονινης | |
| WO2003079887A3 (en) | Measuring blood flow rate or cardiac output | |
| WO2009070442A3 (en) | Fc receptor-mediated tumor necrosis factor superfamily mrna expression in peripheral blood leukocytes | |
| AU2018239989A8 (en) | Methods of measuring signaling pathway activity for selection of therapeutic agents | |
| WO2009064973A3 (en) | Diagnostic kits and methods for scd or sca therapy selection | |
| DE60037116D1 (de) | System zur behandlung eines patienten mit einem medikament zur optimierung der therapie und zur verhinderung eines negativen nebeneffektes | |
| Ashe et al. | Prevention and treatment of bone loss after a spinal cord injury: a systematic review | |
| ATE356994T1 (de) | Screeningverfahren mit pim1-kinase oder pim3- kinase | |
| EP1742643A4 (en) | MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOKASE EXPRESSION | |
| SE0102147D0 (sv) | New methods | |
| WO2007117589A3 (en) | Enhanced fc receptor-mediated tumor necrosis factor superfamily and chemokine mrna expression in peripheral blood leukocytes in patients with rheumatoid arthritis | |
| EA201000630A1 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови | |
| RU2008116567A (ru) | Биомаркеры | |
| Mabilleau et al. | Number of circulating CD14-positive cells and the serum levels of TNF-α are raised in acute charcot foot |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |